Trial-Results center  
Clinical trial results database in 100 Feedback    Home


Related trials

CRIS, 1996 - verapamil vs placebo

SPRINT II, 1993 - nifedipine vs placebo

DAVIT II, 1990 - verapamil vs placebo

Gottlieb, 1988 - nifedipine vs placebo

MDPIT, 1988 - diltiazem vs placebo

SPRINT I, 1988 - nifedipine vs placebo

Zannad, 1988 - diltiazem vs placebo

Erbel, 1988 - nifedipine vs placebo

Walker, 1988 - nifedipine vs placebo

Jaffe, 1987 - nifedipine vs placebo

TRENT (Wilcox), 1986 - nifedipine vs placebo

Machecourt, 1986 - diltiazem vs

Bradagan, 1986 - nifedipine vs placebo

Gibson, 1986 - diltiazem vs placebo

Eichler, 1985 - Tiapamil vs control

Crea, 1985 - verapamil vs placebo

Loogna, 1985 - nifedipine vs placebo

Eisenberg, 1985 - nifedipine vs placebo

Gordon, 1984 - nifedipine vs

Muller, 1984 - nifedipine vs

DAVIT I, 1984 - verapamil vs placebo

Sirnes, 1984 - nifedipine vs placebo

Bussman, 1984 - verapamil vs control

Danish study, 1984 - verapamil vs placebo

MI study group, 1979 - nifedipine vs



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of calcium channel blockers
  • All clinical trials of nifedipine
  •  

    Eisenberg study, 1985

    download pdf: nifedipine | calcium channel blockers for acute myocardial infarction

    Treatments

    Studied treatment Nifedipine 20mgx4
    Control treatment placebo

    Patients

    Patients patients with nontransmural myocardial infarction
    Baseline characteristics
    Time of starting treatment diagnosis 
    Duration of therapy 14 days 

    Method and design

    Randomized effectives 25 / 25 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 12 days
    Primary endpoint chest pain


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    All cause death

    0 / 25
    0 / 25
    classic 1,00 [0,00;248,62]

    confirmed myocardial infarction

    28 / 25
    23 / 25
    classic 1,22 [0,00;248,62]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    All cause death 0 / 25 (2,0%) 0 / 25 (2,0%) 1,00 [0,02;48,45]  
    confirmed myocardial infarction 28 / 25 (112,0%) 23 / 25 (92,0%) 1,22 [0,02;48,45]  
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    confirmed myocardial infarction 112,00% 92,00% 20,0%

    Meta-analysis of all similar trials:

    calcium channel blockers in acute myocardial infarction for acute short term and post MI studies

    calcium channel blockers in acute myocardial infarction for acute (short term) treatment



    Reference(s)

    Trials register # NA
    • Eisenberg PR, Lee RG, Biello DR, Geltman EM, Jaffe AS. Chest pain after nontransmural infarction: the absence of remediable coronary vasospasm.. Am Heart J 1985;110:515-21
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100